Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

Vertex Pharma could be close to succeeding in ... for acute pain applications have revolved mainly around nerve growth factor inhibitors, but the two leaders in the category, Eli Lilly and ...

After hours: February 10 at 6:46:55 PM EST Loading Chart for FORM ...

Northland Securities analyst Gus Richard maintained a Hold rating on Formfactor (FORM – Research Report) today and set a price target of $34.00. The company’s shares closed yesterday at $41.12.

In this article, we are going to take a look at where FormFactor, Inc. (NASDAQ:FORM) stands against the other AI stocks. The evolving space of AI has been a major focus these days, as experts and ...

In a report released yesterday, Vedvati Shrotre from Evercore ISI maintained a Hold rating on Formfactor (FORM – Research Report), with a price target of $43.00. The company’s shares closed ...

Shares of semiconductor testing company FormFactor (NASDAQ:FORM) fell 29.5% in the pre-market session after the company reported a disappointing quarter, with EPS and adjusted operating income ...

Shares of semiconductor testing company FormFactor (NASDAQ:FORM) fell 29.5% in the pre-market session after the company reported a disappointing quarter, with EPS and adjusted operating income missing ...